Haiyang Zhou, MD
Shanghai Changzheng Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Haiyang Zhou, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:49 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07801352 · CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal CancerShanghai Changzheng Hospital · active not recruiting · Locally Advanced Colorectal Cancer, Metastatic Colorectal Cancer · principal investigator
- Ph2NCT05585814 · CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal CancerShanghai Changzheng Hospital · active not recruiting · Locally Advanced Rectal Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in colorectal cancer.